HPA1 Inhibitors
Items 1 to 10 of 13 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
OGT 2115 | 853929-59-6 | sc-204144 | 1 mg | $98.00 | 2 | |
OGT 2115 is a specialized acid halide characterized by its reactivity and selectivity in acylation reactions. Its unique structure allows for rapid formation of acyl-enzyme intermediates, enhancing reaction kinetics with nucleophiles. The presence of halogen atoms promotes electrophilic character, facilitating specific molecular interactions that can lead to the formation of stable covalent bonds. This compound's distinct physical properties, such as its ability to form stable adducts, further influence its reactivity profile in synthetic pathways. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
This compound is a pyrimidine analog that can inhibit DNA synthesis and function as an antineoplastic agent. Its action could potentially lead to a decrease in HPA1 expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
As an antibiotic and antineoplastic agent, it intercalates into DNA, inhibiting transcription. This action might reduce HPA1 mRNA production and consequently its expression. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
It is a topoisomerase I inhibitor, leading to DNA damage and potentially impacting transcription and translation processes, possibly affecting HPA1 expression. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
This platinum-containing compound forms DNA adducts, leading to DNA damage and potentially reduced transcription, affecting proteins like HPA1. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
As an anthracycline antibiotic, it intercalates into DNA and inhibits topoisomerase II, potentially decreasing HPA1 expression indirectly through DNA damage. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
It is a topoisomerase II inhibitor, which can lead to DNA strand breaks and potentially affect transcription, potentially influencing HPA1 expression. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
This ribonucleotide reductase inhibitor can lead to decreased DNA synthesis, potentially affecting transcription and translation processes, including HPA1 expression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
As a dihydrofolate reductase inhibitor, it impacts nucleotide synthesis and can lead to reduced transcription and translation, potentially affecting HPA1. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $66.00 $101.00 $143.00 | 85 | |
This alkylating agent can cause DNA cross-linking, leading to DNA damage and potentially reduced HPA1 expression as a secondary effect. | ||||||